Anbio Biotechnology (NNNN) Gross margin 2022–2025
Anbio Biotechnology (NNNN) gross margin by fiscal year — reported gross profit divided by reported revenue.
87.2%FY2025 · since FY2022: 53.4% → 87.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 87.2% | +15.3 pp |
| FY2024 | 71.9% | +21.8 pp |
| FY2023 | 50.1% | -3.3 pp |
| FY2022 | 53.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NNNN financial trends
NNNN RevenueNNNN Net incomeNNNN Net marginNNNN Gross profitNNNN Operating incomeNNNN Operating marginNNNN Operating cash flowNNNN Free cash flowNNNN Capital expendituresNNNN Return on equityNNNN Stock buybacksNNNN Dividends paidNNNN Total assetsNNNN Total liabilitiesNNNN Shareholders’ equityNNNN overview →